Skip to main content

Advertisement

SpringerLink
Log in

Encapsulation Strategies for Pancreatic Islet Transplantation without Immune Suppression

  • Artificial Tissues (A Atala and J G Hunsberger, Section Editors)
  • Published:
Current Stem Cell Reports Aims and scope Submit manuscript

Abstract

Purpose of Study

Although the current treatment option of exogenous insulin administration for type 1 diabetes mellitus (T1DM) corrects hyperglycemia, it has its own limitations and complications in long-term use. Thus, alternative approaches such as immune therapies, glucose transporter inhibitors, gastro-enteric protein-hormone pathway modulators, and cell- and tissue-based therapies are being developed. Among these therapies, islet transplantation has been shown to be a more physiological means of treating type 1 diabetes. However, the shortage of donor tissues and the use of immunosuppressive agents have led to the development of immune isolation techniques such as cell encapsulation.

Recent findings

Although macroencapsulation of islets has been shown with some success, microencapsulation mostly with permselectively coated alginate hydrogel has been demonstrated to be superior among the variety of developed encapsulation technologies including nanoencapsulation and thus, has led to several clinical trials. While microencapsulated islet transplantation has shown promise in correcting the pathological symptoms of T1DM, the technology still requires improvement in a few areas in order to achieve sustained performance in long-term application.

Summary

Some approaches suggested for improvement include incorporation of immunomodulatory stem cells such as mesenchymal stem cells, substitution of current crosslinking agents with stable safe divalent cations, improving the chemistry of alginate by adding functional groups, and including extracellular matrix (ECM) components of the pancreas in the encapsulated islet construct. With thorough investigation and improvement on the pitfalls of the technology, and more clinical trials, the microencapsulation technology would provide a viable option for a sustainable and more physiological means of insulin delivery in T1DM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bullard KM, et al. Prevalence of diagnosed diabetes in adults by diabetes type - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(12):359–61.

    Article  PubMed  PubMed Central  Google Scholar 

  2. International Diabetes Federation, IDF Diabetes Atlas. 2019: Brussels, Belgium.

  3. CDC report, National Diabetes Statistics Report. 2020: Atlanta, GA, USA.

  4. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2009. 32 Suppl 1(Suppl 1): p. S62-7.

  5. Mobasseri M, et al. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 2020;10(2):98–115.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Maahs DM, et al. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):481–97.

    Article  PubMed  PubMed Central  Google Scholar 

  7. JDRF, Type 1 Diabetes Facts 2020.

  8. Liese AD, et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics. 2006;118(4):1510–8.

    Article  PubMed  Google Scholar 

  9. Dabelea D, et al. Incidence of diabetes in youth in the United States. Jama. 2007;297(24):2716–24.

    Article  PubMed  Google Scholar 

  10. Banting FG, Best CH. Pancreatic extracts. 1922. J Lab Clin Med. 1990;115(2):254–72 This is the original paper that describes the discovery of insulin by Banting and Best in Canada.

    CAS  PubMed  Google Scholar 

  11. Pathak V, et al. Therapies for type 1 diabetes: current scenario and future perspectives. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419844521.

    Article  PubMed  PubMed Central  Google Scholar 

  12. REPOSE Study Group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ 2017. 356: p. j1285. https://doi.org/10.1136/bmj.j1285.

  13. Abramson A, et al. An ingestible self-orienting system for oral delivery of macromolecules. Science. 2019;363(6427):611–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Boughton CK, Hovorka R. Is an artificial pancreas (closed-loop system) for type 1 diabetes effective? Diabet Med. 2019;36(3):279–86.

    Article  CAS  PubMed  Google Scholar 

  15. Kambe N, et al. Impact of newly developed, next-generation artificial endocrine pancreas. J Med Invest. 2015;62(1-2):41–4.

    Article  PubMed  Google Scholar 

  16. Slover RH, et al. Accuracy of a fourth-generation continuous glucose monitoring system in children and adolescents with type 1 diabetes. Diabetes Technol Ther. 2018;20(9):576–84.

    Article  CAS  PubMed  Google Scholar 

  17. Jacobs PG, et al. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. Diabetes Obes Metab. 2016;18(11):1110–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Haidar A, et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2015;3(8):595–604.

    Article  CAS  PubMed  Google Scholar 

  19. Weisman A, et al. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(7):501–12.

    Article  CAS  PubMed  Google Scholar 

  20. Bergenstal RM, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407–8.

    Article  PubMed  Google Scholar 

  21. Bekiari E, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. Bmj. 2018;361:k1310.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Anonymous. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes, 1988. 37(11): p. 1574-82.

  23. Russell G, et al. Mechanisms of action of cyclosporine and effects on connective tissues. Semin Arthritis Rheum. 1992;21(6 Suppl 3):16–22.

    Article  CAS  PubMed  Google Scholar 

  24. Martin S, et al. Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care. 1992;15(1):66–74.

    Article  CAS  PubMed  Google Scholar 

  25. Ludvigsson J. Therapies to preserve β-cell function in type 1 diabetes. Drugs. 2016;76(2):169–85.

    Article  CAS  PubMed  Google Scholar 

  26. Gitelman SE, et al. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia. 2016;59(6):1153–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Moran A, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381(9881):1905–15.

    Article  CAS  PubMed  Google Scholar 

  28. Visperas A, Vignali DA. Are regulatory T cells defective in type 1 diabetes and can we fix them? J Immunol. 2016;197(10):3762–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Takemoto N, et al. Coaggregates of regulatory T cells and islet cells allow long-term graft survival in liver without immunosuppression. Transplantation. 2015;99(5):942–7.

    Article  CAS  PubMed  Google Scholar 

  30. Bluestone JA, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7(315):315–189.

    Article  Google Scholar 

  31. Singha S, et al. Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices. Nat Nanotechnol. 2017;12(7):701–10.

    Article  CAS  PubMed  Google Scholar 

  32. Clemente-Casares X, et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature. 2016;530(7591):434–40.

    Article  CAS  PubMed  Google Scholar 

  33. Millar PJ, et al. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice. Mol Cell Endocrinol. 2016;420:37–45.

    Article  CAS  PubMed  Google Scholar 

  34. van Baar MJB, et al. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care. 2018;41(8):1543–56.

    Article  PubMed  Google Scholar 

  35. Tahara A, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66(7):975–87.

    Article  CAS  PubMed  Google Scholar 

  36. Cheng ST, et al. The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic β-cell mass and glucose homeostasis in type 1 diabetes. PLoS One. 2016;11(1):e0147391.

    Article  PubMed  PubMed Central  Google Scholar 

  37. McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia. 2018;61(10):2126–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Pathak VI, N, Flatt PR, The enteroinsular axis – contribution to obesity-diabetes and its treatments, in nutrition and diabetes: pathophysiology and management, E.C.D.-J. Opara, S., Editor. CRC Press: Boca Raton, FL. 2019, p. 41-56.

  39. Frandsen CS, et al. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study. Diabetes Care. 2015;38(12):2250–7.

    Article  CAS  PubMed  Google Scholar 

  40. Traina AN, et al. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes. 2014;38(4):269–72.

    Article  PubMed  Google Scholar 

  41. Pocai A. Action and therapeutic potential of oxyntomodulin. Mol Metab. 2014;3(3):241–51.

    Article  CAS  PubMed  Google Scholar 

  42. Pathak NM, et al. Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice. Mol Cell Endocrinol. 2015;412:95–103.

    Article  CAS  PubMed  Google Scholar 

  43. Irwin N, et al. Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes. Diabetes Obes Metab. 2015;17(9):887–95.

    Article  CAS  PubMed  Google Scholar 

  44. Khan D, et al. Differential expression of glucagon-like peptide-2 (GLP-2) is involved in pancreatic islet cell adaptations to stress and beta-cell survival. Peptides. 2017;95:68–75.

    Article  CAS  PubMed  Google Scholar 

  45. Khan D, et al. Islet distribution of peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival. Mol Cell Endocrinol. 2016;436:102–13.

    Article  CAS  PubMed  Google Scholar 

  46. Chen S, Du K, Zou C. Current progress in stem cell therapy for type 1 diabetes mellitus. Stem Cell Res Ther. 2020;11(1):275.

    Article  PubMed  PubMed Central  Google Scholar 

  47. de Klerk E, Hebrok M. Stem cell-based clinical trials for diabetes mellitus. Front Endocrinol (Lausanne). 2021;12:631463.

    Article  Google Scholar 

  48. Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;41(9):653–64.

    Article  CAS  PubMed  Google Scholar 

  49. Taylor CJ, et al. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell. 2012;11(2):147–52.

    Article  CAS  PubMed  Google Scholar 

  50. Kondo Y, et al. iPSC technology-based regenerative therapy for diabetes. Journal of Diabetes Investigation. 2018;9(2):234–43.

    Article  PubMed  Google Scholar 

  51. El Khatib MM, et al. β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection. Gene Ther. 2015;22(5):430–8.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Figueiredo C, Blasczyk R. A future with less HLA: potential clinical applications of HLA-universal cells. Tissue Antigens. 2015;85(6):443–9.

    Article  CAS  PubMed  Google Scholar 

  53. Koga K, Wang B, Kaneko S. Current status and future perspectives of HLA-edited induced pluripotent stem cells. Inflammation and Regeneration. 2020;40(1):23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Lee J, et al. Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy. Sci Rep. 2020;10(1):17753.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Gornalusse GG, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017;35(8):765–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Swanson KJ, et al. Incidence and outcomes of significant weight changes after pancreas transplant alone. Transplant Direct. 2020;6(3):e539.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Robertson P, et al. Pancreas transplantation in type 1 diabetes. Diabetes Care. 2004;27(Suppl 1):S105.

    PubMed  Google Scholar 

  58. Hampson FA, et al. Pancreatic transplantation: surgical technique, normal radiological appearances and complications. Insights Imaging. 2010;1(5-6):339–47.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Kelly WD, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61(6):827–37.

    CAS  PubMed  Google Scholar 

  60. Troppmann C. Complications after pancreas transplantation. Curr Opin Organ Transplant. 2010;15(1):112–8.

    Article  PubMed  Google Scholar 

  61. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Clin Transpl. 2008:45–56.

  62. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud. 2011;8(1):6–16.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Dholakia S, et al. Advances in pancreas transplantation. J R Soc Med. 2016;109(4):141–6.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Liong SY, et al. Complications following pancreatic transplantations: imaging features. Abdom Imaging. 2011;36(2):206–14.

    Article  CAS  PubMed  Google Scholar 

  65. Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery. 1972;72(2):175–86.

    CAS  PubMed  Google Scholar 

  66. Sutherland DE, et al. Transplantation of dispersed pancreatic islet tissue in humans: autografts and allografts. Diabetes. 1980;29(Suppl 1):31–44.

    Article  PubMed  Google Scholar 

  67. Ricordi C, et al. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37(4):413–20.

    Article  CAS  PubMed  Google Scholar 

  68. Shapiro AM, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230–8 This paper may be described as the dawn of new era of clinical islet transplantation as it reported extended periods of insulin independence for the first time in several patients after intraportal allo-islet transplantation.

    Article  CAS  PubMed  Google Scholar 

  69. Johansson H, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes. 2005;54(6):1755–62.

    Article  CAS  PubMed  Google Scholar 

  70. Koh A, et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation. 2010;89(4):465–71.

    Article  CAS  PubMed  Google Scholar 

  71. Bottino R, et al. The Future of Islet Transplantation Is Now. Front Med (Lausanne). 2018;5:202.

    Article  Google Scholar 

  72. McCall M, Shapiro AM. Update on islet transplantation. Cold Spring Harb Perspect Med. 2012;2(7):a007823.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Yeh HC, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157(5):336–47.

    Article  PubMed  Google Scholar 

  74. Jacobson AM, et al. The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care. 2013;36(10):3131–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Priya G, Kalra S. A review of insulin resistance in type 1 diabetes: is there a place for adjunctive metformin? Diabetes Ther. 2018;9(1):349–61.

    Article  CAS  PubMed  Google Scholar 

  76. Panero F, et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care. 2009;32(2):301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Johansson BL, et al. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia. 1996;39(6):687–95.

    Article  CAS  PubMed  Google Scholar 

  78. Johansson BL, et al. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med. 2000;17(3):181–9.

    Article  CAS  PubMed  Google Scholar 

  79. Johansson BL, et al. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab. 1993;77(4):976–81.

    CAS  PubMed  Google Scholar 

  80. Johansson BL, Linde B, Wahren J. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia. 1992;35(12):1151–8.

    Article  CAS  PubMed  Google Scholar 

  81. Johansson BL, Sjöberg S, Wahren J. The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients. Diabetologia. 1992;35(2):121–8.

    Article  CAS  PubMed  Google Scholar 

  82. Hills CE, Brunskill NJ. C-Peptide and its intracellular signaling. Rev Diabet Stud. 2009;6(3):138–47.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Wahren J, Ekberg K, Jörnvall H. C-peptide is a bioactive peptide. Diabetologia. 2007;50(3):503–9.

    Article  CAS  PubMed  Google Scholar 

  84. Sima AA, et al. Sequential abnormalities in type 1 diabetic encephalopathy and the effects of C-peptide. Rev Diabet Stud. 2009;6(3):211–22.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Luppi P, Cifarelli V, Wahren J. C-peptide and long-term complications of diabetes. Pediatr Diabetes. 2011;12(3 Pt 2):276–92.

    Article  CAS  PubMed  Google Scholar 

  86. Wahren J, Kallas Å, Sima AAF. The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes. 2012;61(4):761–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Vantyghem MC, et al. Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation. Ann Endocrinol (Paris). 2007;68(1):21–7.

    Article  CAS  Google Scholar 

  88. Froud T, et al. Resolution of neurotoxicity and beta-cell toxicity in an islet transplant recipient following substitution of tacrolimus with MMF. Cell Transplant. 2006;15(7):613–20.

    Article  PubMed  Google Scholar 

  89. Zhang N, et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes. 2006;55(9):2429–36.

    Article  CAS  PubMed  Google Scholar 

  90. Niclauss N, et al. Rapamycin impairs proliferation of transplanted islet β cells. Transplantation. 2011;91(7):714–22.

    Article  CAS  PubMed  Google Scholar 

  91. Hyder A, Laue C, Schrezenmeir J. Effect of the immunosuppressive regime of Edmonton protocol on the long-term in vitro insulin secretion from islets of two different species and age categories. Toxicol In Vitro. 2005;19(4):541–6.

    Article  CAS  PubMed  Google Scholar 

  92. Mense MG, Rosol TJ, Chapter 35 - endocrine pancreas, in Boorman's pathology of the rat (second edition), A.W. Suttie, Editor. Academic Press: Boston.2018, p. 695-704.

  93. Opara EC, Kendall WF Jr. Immunoisolation techniques for islet cell transplantation. Expert Opin Biol Ther. 2002;2(5):503–11.

    Article  PubMed  Google Scholar 

  94. de Vos P, Hamel AF, Tatarkiewicz K. Considerations for successful transplantation of encapsulated pancreatic islets. Diabetologia. 2002;45(2):159–73.

    Article  PubMed  Google Scholar 

  95. de Vos P, van Schilfgaarde R. In: Kühtreiber WM, Lanza RP, Chick WL, editors. Biocompatibility issues, in cell encapsulation technology and therapeutics. Boston, MA: Birkhäuser Boston; 1999. p. 63–75.

    Chapter  Google Scholar 

  96. Bisceglie V. Über die antineoplastische Immunität. Zeitschrift für Krebsforschung. 1934;40(1):122–40.

    Article  Google Scholar 

  97. Aebischer P, et al. Functional recovery in hemiparkinsonian primates transplanted with polymer-encapsulated PC12 cells. Exp Neurol. 1994;126(2):151–8.

    Article  CAS  PubMed  Google Scholar 

  98. Wong H, Chang TM. Bioartificial liver: implanted artificial cells microencapsulated living hepatocytes increases survival of liver failure rats. Int J Artif Organs. 1986;9(5):335–6.

    Article  CAS  PubMed  Google Scholar 

  99. Cieslinski DA, David Humes H. Tissue engineering of a bioartificial kidney. Biotechnol Bioeng. 1994;43(7):678–81.

    Article  CAS  PubMed  Google Scholar 

  100. Chang TM. Semipermeable microcapsules. Science. 1964;146(3643):524–5.

    Article  CAS  PubMed  Google Scholar 

  101. Koo J, Chang TM. Secretion of erythropoietin from microencapsulated rat kidney cells: preliminary results. Int J Artif Organs. 1993;16(7):557–60.

    Article  CAS  PubMed  Google Scholar 

  102. Prehn RT, Weaver JM, Algire GH. The diffusion-chamber technique applied to a study of the nature of homograft resistance. J Natl Cancer Inst. 1954;15(3):509–17.

    CAS  PubMed  Google Scholar 

  103. Elliott RB, et al. Transplantation of micro- and macroencapsulated piglet islets into mice and monkeys. Transplant Proc. 2005;37(1):466–9.

    Article  CAS  PubMed  Google Scholar 

  104. Dufrane D, et al. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation. 2006;81(9):1345–53.

    Article  PubMed  Google Scholar 

  105. Abalovich AG, et al. Pig pancreatic islet transplantation into spontaneously diabetic dogs. Transplant Proc. 2009;41(1):328–30.

    Article  CAS  PubMed  Google Scholar 

  106. Wang T, et al. Successful allotransplantation of encapsulated islets in pancreatectomized canines for diabetic management without the use of immunosuppression. Transplantation. 2008;85(3):331–7.

    Article  PubMed  Google Scholar 

  107. Meyer T, Höcht B, Ulrichs K. Xenogeneic islet transplantation of microencapsulated porcine islets for therapy of type I diabetes: long-term normoglycemia in STZ-diabetic rats without immunosuppression. Pediatr Surg Int. 2008;24(12):1375–8.

    Article  PubMed  Google Scholar 

  108. Foster JL, et al. Differentiation of transplanted microencapsulated fetal pancreatic cells. Transplantation. 2007;83(11):1440–8.

    Article  PubMed  Google Scholar 

  109. Soon-Shiong P, et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet. 1994;343(8903):950–1.

    Article  CAS  PubMed  Google Scholar 

  110. Tuch BE, et al. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care. 2009;32(10):1887–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Calafiore R, et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care. 2006;29(1):137–8.

    Article  PubMed  Google Scholar 

  112. Scharp DW, Mason NS, Sparks RE. Islet immuno-isolation: the use of hybrid artificial organs to prevent islet tissue rejection. World J Surg. 1984;8(2):221–9.

    Article  CAS  PubMed  Google Scholar 

  113. Lanza RP, Hayes JL, Chick WL. Encapsulated cell technology. Nat Biotechnol. 1996;14(9):1107–11.

    Article  CAS  PubMed  Google Scholar 

  114. Colton CK, Avgoustiniatos ES. Bioengineering in development of the hybrid artificial pancreas. J Biomech Eng. 1991;113(2):152–70.

    Article  CAS  PubMed  Google Scholar 

  115. Chick WL, Like AA, Lauris V. Beta cell culture on synthetic capillaries: an artificial endocrine pancreas. Science. 1975;187(4179):847–9.

    Article  CAS  PubMed  Google Scholar 

  116. Maki T, et al. Treatment of diabetes by xenogeneic islets without immunosuppression. Use of a vascularized bioartificial pancreas. Diabetes. 1996;45(3):342–7.

    Article  CAS  PubMed  Google Scholar 

  117. Maki T, et al. Treatment of severe diabetes mellitus for more than one year using a vascularized hybrid artificial pancreas. Transplantation. 1993;55(4):713–7 discussion 717-8.

    Article  CAS  PubMed  Google Scholar 

  118. Lacy PE, et al. Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. Science. 1991;254(5039):1782–4.

    Article  CAS  PubMed  Google Scholar 

  119. Jain K, et al. Glucose control and long-term survival in biobreeding/Worcester rats after intraperitoneal implantation of hydrophilic macrobeads containing porcine islets without immunosuppression. Transplantation. 1999;68(11):1693–700.

    Article  CAS  PubMed  Google Scholar 

  120. Scharp DW, et al. Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects. Diabetes. 1994;43(9):1167–70 This is one of the first reports of encapsulation as an effective strategy for islet immunoisolation in clinical transplantation.

    Article  CAS  PubMed  Google Scholar 

  121. Storrs R, et al. Preclinical development of the islet sheet. Ann N Y Acad Sci. 2001;944:252–66.

    Article  CAS  PubMed  Google Scholar 

  122. van Suylichem PT, et al. Insulin secretion by rat islet isografts of a defined endocrine volume after transplantation to three different sites. Diabetologia. 1992;35(10):917–23.

    Article  PubMed  Google Scholar 

  123. de Vos P, et al. Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials. 2006;27(32):5603–17.

    Article  PubMed  Google Scholar 

  124. Iwata H, et al. Evaluation of microencapsulated islets in agarose gel as bioartificial pancreas by studies of hormone secretion in culture and by xenotransplantation. Diabetes. 1989;38(Suppl 1):224–5.

    Article  PubMed  Google Scholar 

  125. Cruise GM, et al. In vitro and in vivo performance of porcine islets encapsulated in interfacially photopolymerized poly(ethylene glycol) diacrylate membranes. Cell Transplant. 1999;8(3):293–306.

    Article  CAS  PubMed  Google Scholar 

  126. Zielinski BA, Aebischer P. Chitosan as a matrix for mammalian cell encapsulation. Biomaterials. 1994;15(13):1049–56.

    Article  CAS  PubMed  Google Scholar 

  127. Haug A, Larsen B, A study on the constitution of alginic acid by partial acid hydrolysis, in Proceedings of the fifth international seaweed symposium, Halifax, August 25–28, 1965, E.G. Young and J.L. McLachlan, Editors. Pergamon. 1966, p. 271-277.

  128. Enck, K., et al., Effect of alginate matrix engineered to mimic the pancreatic microenvironment on encapsulated islet function. Biotechnol Bioeng, 2020.

  129. Zhang J, et al. Influence of divalent cations on the biofouling behaviors of alginate hydrogels. Biomed Mater. 2019;15(1):015003.

    Article  PubMed  Google Scholar 

  130. Mørch YA, et al. Effect of Ca2+, Ba2+, and Sr2+ on alginate microbeads. Biomacromolecules. 2006;7(5):1471–80.

    Article  PubMed  Google Scholar 

  131. Tao H, et al. Inconceivable hypokalemia: a case report of acute severe barium chloride poisoning. Case Reports in Medicine. 2016;2016:2743134.

    Article  PubMed  PubMed Central  Google Scholar 

  132. Bhoelan BS, et al. Barium toxicity and the role of the potassium inward rectifier current. Clinical Toxicology. 2014;52(6):584–93.

    Article  CAS  PubMed  Google Scholar 

  133. Struyk AF, Cannon SC. Paradoxical depolarization of BA2+- treated muscle exposed to low extracellular K+: insights into resting potential abnormalities in hypokalemic paralysis. Muscle & Nerve. 2008;37(3):326–37.

    Article  CAS  Google Scholar 

  134. Brady SA, et al. Optimisation of a novel glass-alginate hydrogel for the treatment of intracranial aneurysms. Carbohydr Polym. 2017;176:227–35.

    Article  CAS  PubMed  Google Scholar 

  135. Kang S-M, et al., Alginate microencapsulation for three-dimensional In vitro cell culture. ACS Biomaterials Science & Engineering, 2020.

  136. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science. 1980;210(4472):908–10 This is the first report that described microencapsulated islets as a bioartificial pancreas and demonstrated its efficacy in streptozotocin-induced diabetic rats.

    Article  CAS  PubMed  Google Scholar 

  137. Rabanel JM, et al. Progress technology in microencapsulation methods for cell therapy. Biotechnol Prog. 2009;25(4):946–63.

    Article  CAS  PubMed  Google Scholar 

  138. Wolters GH, et al. A versatile alginate droplet generator applicable for microencapsulation of pancreatic islets. J Appl Biomater. 1991;3(4):281–6.

    Article  CAS  PubMed  Google Scholar 

  139. Opara EC, McQuilling JP, Farney AC. Microencapsulation of pancreatic islets for use in a bioartificial pancreas. Methods Mol Biol. 2013;1001:261–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Omer A, et al. Long-term normoglycemia in rats receiving transplants with encapsulated islets. Transplantation. 2005;79(1):52–8.

    Article  CAS  PubMed  Google Scholar 

  141. Liaudanskaya V, et al. Assessing the impact of electrohydrodynamic jetting on encapsulated cell viability, proliferation, and ability to self-assemble in three-dimensional structures. Tissue Eng Part C Methods. 2015;21(6):631–8.

    Article  CAS  PubMed  Google Scholar 

  142. Ma M, et al. Core-shell hydrogel microcapsules for improved islets encapsulation. Adv Healthc Mater. 2013;2(5):667–72.

    Article  CAS  PubMed  Google Scholar 

  143. Weibel DB, Diluzio WR, Whitesides GM. Microfabrication meets microbiology. Nat Rev Microbiol. 2007;5(3):209–18.

    Article  CAS  PubMed  Google Scholar 

  144. Choi JK, et al. The crucial role of mechanical heterogeneity in regulating follicle development and ovulation with engineered ovarian microtissue. Biomaterials. 2014;35(19):5122–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Headen DM, et al. Microfluidic-based generation of size-controlled, biofunctionalized synthetic polymer microgels for cell encapsulation. Adv Mater. 2014;26(19):3003–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Weaver JD, et al. Synthetic poly(ethylene glycol)-based microfluidic islet encapsulation reduces graft volume for delivery to highly vascularized and retrievable transplant site. Am J Transplant. 2019;19(5):1315–27.

    Article  CAS  PubMed  Google Scholar 

  147. Enck K, et al. Design of an adhesive film-based microfluidic device for alginate hydrogel-based cell encapsulation. Ann Biomed Eng. 2020;48(3):1103–11.

    Article  PubMed  Google Scholar 

  148. Tendulkar S, et al. A scalable microfluidic device for the mass production of microencapsulated islets. Transplant Proc. 2011;43(9):3184–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Tendulkar S, et al. A three-dimensional microfluidic approach to scaling up microencapsulation of cells. Biomed Microdevices. 2012;14(3):461–9.

    Article  CAS  PubMed  Google Scholar 

  150. Boontheekul T, Kong HJ, Mooney DJ. Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials. 2005;26(15):2455–65.

    Article  CAS  PubMed  Google Scholar 

  151. Ashimova, A., et al., Cell encapsulation within alginate microcapsules: immunological challenges and outlook. Frontiers in Bioengineering and Biotechnology, 2019. 7(380).

  152. Lanza RP, et al. Xenotransplantation of porcine and bovine islets without immunosuppression using uncoated alginate microspheres. Transplantation. 1995;59(10):1377–84.

    Article  CAS  PubMed  Google Scholar 

  153. Cui H, et al. Long-term metabolic control of autoimmune diabetes in spontaneously diabetic nonobese diabetic mice by nonvascularized microencapsulated adult porcine islets. Transplantation. 2009;88(2):160–9.

    Article  PubMed  Google Scholar 

  154. Paredes-Juarez GA, et al. DAMP production by human islets under low oxygen and nutrients in the presence or absence of an immunoisolating-capsule and necrostatin-1. Sci Rep. 2015;5:14623.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Vaithilingam V, et al. Characterisation of the xenogeneic immune response to microencapsulated fetal pig islet-like cell clusters transplanted into immunocompetent C57BL/6 mice. PLoS One. 2013;8(3):e59120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Vaithilingam V, et al. Effect of prolonged gelling time on the intrinsic properties of barium alginate microcapsules and its biocompatibility. J Microencapsul. 2011;28(6):499–507.

    Article  CAS  PubMed  Google Scholar 

  157. Kendall WF Jr, Opara EC. Polymeric materials for perm-selective coating of alginate microbeads. Methods Mol Biol. 2017;1479:95–109.

    Article  CAS  PubMed  Google Scholar 

  158. de Vos P, Hoogmoed CG, Busscher HJ. Chemistry and biocompatibility of alginate-PLL capsules for immunoprotection of mammalian cells. J Biomed Mater Res. 2002;60(2):252–9.

    Article  PubMed  Google Scholar 

  159. Sittadjody S, et al. Encapsulation of mesenchymal stem cells in 3D ovarian cell constructs promotes stable and long-term hormone secretion with improved physiological outcomes in a syngeneic Rat model. Ann Biomed Eng. 2020;48(3):1058–70.

    Article  PubMed  Google Scholar 

  160. Sittadjody S, et al. In vivo transplantation of 3D encapsulated ovarian constructs in rats corrects abnormalities of ovarian failure. Nat Commun. 2017;8(1):1858.

    Article  PubMed  PubMed Central  Google Scholar 

  161. Darrabie MD, Kendall WF Jr, Opara EC. Characteristics of poly-L-ornithine-coated alginate microcapsules. Biomaterials. 2005;26(34):6846–52.

    Article  CAS  PubMed  Google Scholar 

  162. Pareta R, et al. Long-term function of islets encapsulated in a redesigned alginate microcapsule construct in omentum pouches of immune-competent diabetic rats. Pancreas. 2014;43(4):605–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. McQuilling JP, et al. Applications of particulate oxygen-generating substances (POGS) in the bioartificial pancreas. Biomater Sci. 2017;5(12):2437–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Krol S, et al. Multilayer nanoencapsulation. New approach for immune protection of human pancreatic islets. Nano Lett. 2006;6(9):1933–9.

    Article  CAS  PubMed  Google Scholar 

  165. Kozlovskaya V, et al. Ultrathin polymeric coatings based on hydrogen-bonded polyphenol for protection of pancreatic islet cells. Adv Funct Mater. 2012;22(16):3389–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. Zhi ZL, Khan F, Pickup JC. Multilayer nanoencapsulation: a nanomedicine technology for diabetes research and management. Diabetes Res Clin Pract. 2013;100(2):162–9.

    Article  PubMed  Google Scholar 

  167. Wilson JT, et al. Noncovalent cell surface engineering with cationic graft copolymers. J Am Chem Soc. 2009;131(51):18228–9.

    Article  CAS  PubMed  Google Scholar 

  168. Wilson JT, Cui W, Chaikof EL. Layer-by-layer assembly of a conformal nanothin PEG coating for intraportal islet transplantation. Nano Lett. 2008;8(7):1940–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  169. Luan NM, Teramura Y, Iwata H. Layer-by-layer co-immobilization of soluble complement receptor 1 and heparin on islets. Biomaterials. 2011;32(27):6487–92.

    Article  PubMed  Google Scholar 

  170. Tatsumi K, et al. The non-invasive cell surface modification of hepatocytes with PEG-lipid derivatives. Biomaterials. 2012;33(3):821–8.

    Article  CAS  PubMed  Google Scholar 

  171. Teramura Y, Kaneda Y, Iwata H. Islet-encapsulation in ultra-thin layer-by-layer membranes of poly(vinyl alcohol) anchored to poly(ethylene glycol)-lipids in the cell membrane. Biomaterials. 2007;28(32):4818–25.

    Article  CAS  PubMed  Google Scholar 

  172. Shih H, Mirmira RG, Lin CC. Visible light-initiated interfacial thiol-norbornene photopolymerization for forming islet surface conformal coating. J Mater Chem B. 2015;3(2):170–5.

    Article  CAS  PubMed  Google Scholar 

  173. Lee DY, et al. Optimization of monomethoxy-polyethylene glycol grafting on the pancreatic islet capsules. J Biomed Mater Res. 2002;62(3):372–7.

    Article  CAS  PubMed  Google Scholar 

  174. Scharp DW, Marchetti P. Encapsulated islets for diabetes therapy: history, current progress, and critical issues requiring solution. Adv Drug Deliv Rev. 2014;67-68:35–73.

    Article  CAS  PubMed  Google Scholar 

  175. Teramura Y, Iwata H. Bioartificial pancreas microencapsulation and conformal coating of islet of Langerhans. Adv Drug Deliv Rev. 2010;62(7-8):827–40.

    Article  CAS  PubMed  Google Scholar 

  176. Zhi ZL, et al. Polysaccharide multilayer nanoencapsulation of insulin-producing beta-cells grown as pseudoislets for potential cellular delivery of insulin. Biomacromolecules. 2010;11(3):610–6.

    Article  CAS  PubMed  Google Scholar 

  177. Teramura Y, Iwata H. Improvement of graft survival by surface modification with poly(ethylene glycol)-lipid and urokinase in intraportal islet transplantation. Transplantation. 2011;91(3):271–8.

    Article  CAS  PubMed  Google Scholar 

  178. Kizilel S, et al. Encapsulation of pancreatic islets within nano-thin functional polyethylene glycol coatings for enhanced insulin secretion. Tissue Eng Part A. 2010;16(7):2217–28.

    Article  CAS  PubMed  Google Scholar 

  179. Miura S, Teramura Y, Iwata H. Encapsulation of islets with ultra-thin polyion complex membrane through poly(ethylene glycol)-phospholipids anchored to cell membrane. Biomaterials. 2006;27(34):5828–35.

    Article  CAS  PubMed  Google Scholar 

  180. Veerabadran NG, et al. Nanoencapsulation of stem cells within polyelectrolyte multilayer shells. Macromol Biosci. 2007;7(7):877–82.

    Article  CAS  PubMed  Google Scholar 

  181. Vaithilingam V, Bal S, Tuch BE. Encapsulated islet transplantation: where do we stand? Rev Diabet Stud. 2017;14(1):51–78.

    Article  PubMed  PubMed Central  Google Scholar 

  182. O'Sullivan ES, et al. Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain. Endocr Rev. 2011;32(6):827–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  183. Phelps EA, et al. Maleimide cross-linked bioactive PEG hydrogel exhibits improved reaction kinetics and cross-linking for cell encapsulation and in situ delivery. Adv Mater. 2012;24(1):64–70 2.

    Article  CAS  PubMed  Google Scholar 

  184. Hwang PT, et al. Progress and challenges of the bioartificial pancreas. Nano Converg. 2016;3(1):28.

    Article  PubMed  PubMed Central  Google Scholar 

  185. Dufrane D, Goebbels RM, Gianello P. Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation. 2010;90(10):1054–62.

    Article  PubMed  Google Scholar 

  186. Ludwig B, et al. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci U S A. 2013;110(47):19054–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Ludwig B, et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A. 2012;109(13):5022–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Neufeld T, et al. The efficacy of an immunoisolating membrane system for islet xenotransplantation in minipigs. PLoS One. 2013;8(8):e70150.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  189. Farina M, et al. Cell encapsulation: overcoming barriers in cell transplantation in diabetes and beyond. Adv Drug Deliv Rev. 2019;139:92–115.

    Article  CAS  PubMed  Google Scholar 

  190. Berman DM, et al. Bioengineering the endocrine pancreas: intraomental islet transplantation within a biologic resorbable scaffold. Diabetes. 2016;65(5):1350–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  191. An D, et al. Designing a retrievable and scalable cell encapsulation device for potential treatment of type 1 diabetes. Proc Natl Acad Sci U S A. 2018;115(2):E263–e272.

    Article  CAS  PubMed  Google Scholar 

  192. Dufrane DM, M, Goffin E, Aouassar N, Gianello P, Vandeleene B. A simple and safe clinical procedure for human encapsulated islet transplantation in the subcutaneous tissue for diabetes treatment. Transplantation. 2013;96:S43.

    Google Scholar 

  193. Espona-Noguera A, et al. Review of advanced hydrogel-based cell encapsulation systems for insulin delivery in type 1 diabetes mellitus. Pharmaceutics. 2019;11(11):597.

    Article  CAS  PubMed Central  Google Scholar 

  194. Kepsutlu B, et al. Design of bioartificial pancreas with functional micro/nano-based encapsulation of islets. Curr Pharm Biotechnol. 2014;15(7):590–608.

    Article  CAS  PubMed  Google Scholar 

  195. Skrzypek K, et al. Pancreatic islet macroencapsulation using microwell porous membranes. Scientific Reports. 2017;7(1):9186.

    Article  PubMed  PubMed Central  Google Scholar 

  196. Dufrane D, Gianello P. Macro- or microencapsulation of pig islets to cure type 1 diabetes. World J Gastroenterol. 2012;18(47):6885–93.

    Article  PubMed  PubMed Central  Google Scholar 

  197. Thevenot P, Hu W, Tang L. Surface chemistry influences implant biocompatibility. Curr Top Med Chem. 2008;8(4):270–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  198. Strand BL, et al. Poly-L-lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant. 2001;10(3):263–75.

    Article  CAS  PubMed  Google Scholar 

  199. Sun Y, et al. Normalization of diabetes in spontaneously diabetic cynomolgus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest. 1996;98(6):1417–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  200. Duvivier-Kali VF, et al. Complete protection of islets against allorejection and autoimmunity by a simple barium-alginate membrane. Diabetes. 2001;50(8):1698–705.

    Article  CAS  PubMed  Google Scholar 

  201. Shimoda M, Matsumoto S. Update regarding xenotransplantation in Japan. Xenotransplantation. 2019;26(1):e12491.

    Article  PubMed  Google Scholar 

  202. Basta G, Montanucci P, Calafiore R, Microencapsulation of cells and molecular therapy of type 1 diabetes mellitus: the actual state and future perspectives between promise and progress. J Diabetes Investig, 2020.

  203. Qi M. Transplantation of encapsulated pancreatic islets as a treatment for patients with type 1 diabetes mellitus. Adv Med. 2014;2014:429710.

    Article  PubMed  PubMed Central  Google Scholar 

  204. Hill RS, et al. Immunoisolation of adult porcine islets for the treatment of diabetes mellitus. The use of photopolymerizable polyethylene glycol in the conformal coating of mass-isolated porcine islets. Ann N Y Acad Sci. 1997;831:332–43.

    Article  CAS  PubMed  Google Scholar 

  205. Soon-Shiong P, et al. Successful reversal of spontaneous diabetes in dogs by intraperitoneal microencapsulated islets. Transplantation. 1992;54(5):769–74.

    Article  CAS  PubMed  Google Scholar 

  206. Dionne KE, Colton CK, Yarmush ML. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes. 1993;42(1):12–21.

    Article  CAS  PubMed  Google Scholar 

  207. Sato Y, et al. Cellular hypoxia of pancreatic beta-cells due to high levels of oxygen consumption for insulin secretion in vitro. J Biol Chem. 2011;286(14):12524–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  208. Hilbrands R, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes. 2009;58(10):2267–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  209. De Vos P, et al. Improved biocompatibility but limited graft survival after purification of alginate for microencapsulation of pancreatic islets. Diabetologia. 1997;40(3):262–70.

    Article  PubMed  Google Scholar 

  210. Paredes-Juarez GA, et al. A technology platform to test the efficacy of purification of alginate. Materials (Basel). 2014;7(3):2087–103.

    Article  Google Scholar 

  211. Krishnan R, et al. Immunological challenges facing translation of alginate encapsulated porcine islet xenotransplantation to human clinical trials. Methods Mol Biol. 2017;1479:305–33.

    Article  CAS  PubMed  Google Scholar 

  212. Dorrington MG, Fraser IDC. NF-κB signaling in macrophages: dynamics, crosstalk, and signal integration. Front Immunol. 2019;10:705.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  213. Vaure C, Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front Immunol. 2014;5:316.

    Article  PubMed  PubMed Central  Google Scholar 

  214. Flo TH, et al. Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers. J Biol Chem. 2002;277(38):35489–95.

    Article  CAS  PubMed  Google Scholar 

  215. Hu S, de Vos P. Polymeric approaches to reduce tissue responses against devices applied for islet-cell encapsulation. Front Bioeng Biotechnol. 2019;7:134.

    Article  PubMed  PubMed Central  Google Scholar 

  216. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301–5.

    Article  CAS  PubMed  Google Scholar 

  217. Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat Immunol. 2007;8(1):11–3.

    Article  CAS  PubMed  Google Scholar 

  218. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8(4):279–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  219. Fullagar B, et al. Nano-encapsulation of bilirubin in pluronic F127-chitosan improves uptake in β cells and increases islet viability and function after hypoxic stress. Cell Transplant. 2017;26(10):1703–15.

    Article  PubMed  PubMed Central  Google Scholar 

  220. Suvarnapathaki S, et al. Breathing life into engineered tissues using oxygen-releasing biomaterials. NPG Asia Materials. 2019;11(1):65.

    Article  CAS  Google Scholar 

  221. Mouré A, et al. Extracellular hemoglobin combined with an O(2) -generating material overcomes O(2) limitation in the bioartificial pancreas. Biotechnol Bioeng. 2019;116(5):1176–89.

    Article  PubMed  Google Scholar 

  222. Stiegler P, et al. Prevention of oxidative stress in porcine islet isolation. J Artif Organs. 2010;13(1):38–47.

    Article  CAS  PubMed  Google Scholar 

  223. Wang H, et al. Bilirubin can induce tolerance to islet allografts. Endocrinology. 2006;147(2):762–8.

    Article  CAS  PubMed  Google Scholar 

  224. Adin CA, et al. Physiologic doses of bilirubin contribute to tolerance of islet transplants by suppressing the innate immune response. Cell Transplant. 2017;26(1):11–21.

    Article  PubMed  PubMed Central  Google Scholar 

  225. Adin CA, Croker BP, Agarwal A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol. 2005;288(4):F778–84.

    Article  CAS  PubMed  Google Scholar 

  226. Krishnan RK, D, Tucker T, Opara E, Foster CE, Imagawa D, et al. Strategies to combat hypoxia in encapsulated islet transplantation. Surgery Curr Res. 2016;6(2):259.

    Article  Google Scholar 

  227. Papas KK, et al. Oxygenation strategies for encapsulated islet and beta cell transplants. Adv Drug Deliv Rev. 2019;139:139–56.

    Article  CAS  PubMed  Google Scholar 

  228. Khanna O, et al. Synthesis of multilayered alginate microcapsules for the sustained release of fibroblast growth factor-1. J Biomed Mater Res A. 2010;95(2):632–40.

    Article  PubMed  PubMed Central  Google Scholar 

  229. Lembert N, et al. Encapsulation of islets in rough surface, hydroxymethylated polysulfone capillaries stimulates VEGF release and promotes vascularization after transplantation. Cell Transplantation. 2005;14(2-3):97–108.

    Article  PubMed  Google Scholar 

  230. Sigrist S, et al. Induction of angiogenesis in omentum with vascular endothelial growth factor: influence on the viability of encapsulated rat pancreatic islets during transplantation. J Vasc Res. 2003;40(4):359–67.

    Article  CAS  PubMed  Google Scholar 

  231. Trivedi N, et al. Improved vascularization of planar membrane diffusion devices following continuous infusion of vascular endothelial growth factor. Cell Transplant. 2000;9(1):115–24.

    Article  CAS  PubMed  Google Scholar 

  232. Weaver JD, et al. Design of a vascularized synthetic poly(ethylene glycol) macroencapsulation device for islet transplantation. Biomaterials. 2018;172:54–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  233. Ludwig B, et al. Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proc Natl Acad Sci U S A. 2010;107(28):12623–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  234. Vaithilingam V, et al. Beneficial effects of desferrioxamine on encapsulated human islets--in vitro and in vivo study. Am J Transplant. 2010;10(9):1961–9.

    Article  CAS  PubMed  Google Scholar 

  235. Opara EC, et al. Design of a bioartificial pancreas(+). J Investig Med. 2010;58(7):831–7.

    Article  PubMed  PubMed Central  Google Scholar 

  236. Smink AM, de Vos P. Therapeutic strategies for modulating the extracellular matrix to improve pancreatic islet function and survival after transplantation. Curr Diab Rep. 2018;18(7):39.

    Article  PubMed  PubMed Central  Google Scholar 

  237. Llacua LA, de Haan BJ, de Vos P. Laminin and collagen IV inclusion in immunoisolating microcapsules reduces cytokine-mediated cell death in human pancreatic islets. J Tissue Eng Regen Med. 2018;12(2):460–7.

    Article  CAS  PubMed  Google Scholar 

  238. Yan J, Chen F, Amsden BG. Cell sheets prepared via gel-sol transition of calcium RGD-alginate. Acta Biomater. 2016;30:277–84.

    Article  CAS  PubMed  Google Scholar 

  239. Kang SW, et al. The effect of conjugating RGD into 3D alginate hydrogels on adipogenic differentiation of human adipose-derived stromal cells. Macromol Biosci. 2011;11(5):673–9.

    Article  CAS  PubMed  Google Scholar 

  240. Kreeger PK, et al. The in vitro regulation of ovarian follicle development using alginate-extracellular matrix gels. Biomaterials. 2006;27(5):714–23.

    Article  CAS  PubMed  Google Scholar 

  241. Jo EH, Hwang YH, Lee DY. Encapsulation of pancreatic islet with HMGB1 fragment for attenuating inflammation. Biomater Res. 2015;19:21.

    Article  PubMed  PubMed Central  Google Scholar 

  242. Dang TT, et al. Enhanced function of immuno-isolated islets in diabetes therapy by co-encapsulation with an anti-inflammatory drug. Biomaterials. 2013;34(23):5792–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  243. Vaithilingam V, et al. Co-encapsulation and co-transplantation of mesenchymal stem cells reduces pericapsular fibrosis and improves encapsulated islet survival and function when allografted. Scientific Reports. 2017;7(1):10059.

    Article  PubMed  PubMed Central  Google Scholar 

  244. Fransson M, et al. Mesenchymal stromal cells support endothelial cell interactions in an intramuscular islet transplantation model. Regen Med Res. 2015;3:1.

    Article  PubMed  PubMed Central  Google Scholar 

  245. Hamilton DC, et al. A silk-based encapsulation platform for pancreatic islet transplantation improves islet function in vivo. J Tissue Eng Regen Med. 2017;11(3):887–95.

    Article  CAS  PubMed  Google Scholar 

  246. Cantú-Rodríguez OG, et al. Long-term insulin independence in type 1 diabetes mellitus using a simplified autologous stem cell transplant. J Clin Endocrinol Metab. 2016;101(5):2141–8.

    Article  PubMed  Google Scholar 

  247. Jacobs-Tulleneers-Thevissen D, et al. Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia. 2013;56(7):1605–14.

    Article  CAS  PubMed  Google Scholar 

  248. Basta G, et al. Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: four cases. Diabetes Care. 2011;34(11):2406–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  249. Close N, et al. NIH-supported National Islet Transplantation Registry. Cell Biochem Biophys. 2004;40(3 Suppl):9–18.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank all the students and fellows that have worked with Dr. Opara in the microencapsulation technology over the years as their findings have contributed to the knowledge shared in this review article.

Author information

Authors and Affiliations

  1. Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 27101, USA

    Sivanandane Sittadjody & Emmanuel C. Opara

  2. Virginia Tech-Wake Forest School of Biomedical Engineering & Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 27101, USA

    Emmanuel C. Opara

Authors
  1. Sivanandane Sittadjody
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emmanuel C. Opara
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Sittadjody S performed the literature search and generated a draft of the manuscript. Opara EC conceived the idea, generated the outline for the review, and critically edited the manuscript.

Corresponding author

Correspondence to Emmanuel C. Opara.

Ethics declarations

Conflict of Interest

The authors declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Artificial Tissues

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sittadjody, S., Opara, E.C. Encapsulation Strategies for Pancreatic Islet Transplantation without Immune Suppression. Curr Stem Cell Rep 7, 49–71 (2021). https://doi.org/10.1007/s40778-021-00190-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40778-021-00190-w

Keywords

Search

Navigation